OncLive TV

Jonathan D. Spicer, MD, PhD, FRCS, discusses surgical considerations for patients with for resectable NSCLC after the approval of perioperative nivolumab.

Daniel DeAngelo, MD, PhD, discusses the evolving role of JAK inhibitors in the management of myelofibrosis and highlights remaining unmet needs for this patient population.

Marc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.

Douglas W. Sborov, MD, MS, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Daniel DeAngelo MD, PhD, discusses current treatment strategies for patients with myelofibrosis, highlighting ongoing and recently presented studies

Casey M. Cosgrove, MD, discusses treatment with the ADC T-DXd in patients with ovarian cancer.

Ashraf Z. Badros, MBCHB, discusses the design of the AURIGA trial of daratumumab plus lenalidomide in newly diagnosed myeloma following transplant.

Bradley C. Carthon, MD, PhD, discusses treatment with darolutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

David C. Fisher, MD, discusses treatment with bispecific antibodies and CAR T-cell therapy, respectively, for patients with cytokine release syndrome.

Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma

Binod Dhakal, MD, discusses key trials presented at the 21st International Myeloma Society Annual Meeting in patients with multiple myeloma.

Michel Delforge, MD, PhD, discusses the efficacy of cilta-cel in CARTITUDE-4 vs alternative approaches for lenalidomide-refractory myeloma.

Sheldon M. Feldman, MD, discusses how the use of personalized medicine has evolved in breast cancer management.

Casey M. Cosgrove, MD, discusses the evolution of treatment with antibody-drug conjugates for patients with ovarian cancer.

Aparna Parikh, MD, discusses currently available targeted therapy options for patients with colorectal cancer.

Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.

Alan Tan, MD, discusses long-term data guiding the selection of immuno-oncology combination regimens in advanced renal cell carcinoma.

Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.

Roy S. Herbst, MD, PhD, discusses ongoing, planned, and future research for the management of unmutated non–small cell lung cancer.

Sheldon M. Feldman, MD, discusses the importance of Breast Cancer Awareness Month as well as timely screening and early detection.

Laura J. Chambers, DO, discusses the importance of treatment counseling for patients with ovarian cancer considering PARP inhibitor therapy.

Thomas Westbrook, MD, discusses the evolving understanding of non–clear cell renal cell carcinoma subtypes and implications for clinical practice.

Massimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.

Ajay K. Nooka, MD, MPH, FACP, discusses the integration of bispecific antibodies into the community treatment paradigm for multiple myeloma.

Matthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.

David S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Tanios Bekaii-Saab, MD, FACP, discusses the evolving treatment paradigm for BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting.

Farrukh Awan, MD, discuses the evolving role of bispecific antibodies in the treatment paradigm of diffuse large B-cell lymphoma.